Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
about
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsyTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesThe role of surgeons in building a personalized medicine programThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisThe evolution of the locoregional therapy of breast cancerHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenTailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer.Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifenPhase II open-label study of sunitinib in patients with advanced breast cancer.Cancer Risk after Fat Transfer: A Multicenter Case-Cohort StudyPostmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.Pathogenesis, prevention, diagnosis and treatment of breast cancer.Tumor gene expression profiling in women with breast cancer. Test category: prognostic.Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.Regional Nodal Irradiation in Early-Stage Breast Cancer.New insight into Ki67 expression at the invasive front in breast cancer.The impact of age on outcome in early-stage breast cancerUnderstanding the economic value of molecular diagnostic tests: case studies and lessons learned.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigaThe 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.Review of the clinical studies using the 21-gene assay.The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.Optimal management of sentinel lymph node positive biopsy patients in early breast cancer.Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription ProfilingCancer biomarker discovery and validation.The implications of breast cancer molecular phenotype for radiation oncology.Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.Tailoring cancer radiotherapy through genotyping, how close are we?Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
P2860
Q26747688-42AF6E9C-B4FB-42B0-909A-FABF70E0327AQ26768119-3B0D426A-4F69-4787-B4E4-5202270C6C37Q26849667-4981CF58-92B6-4287-A205-33BF8B897669Q26861418-3885178B-BFD2-4ADF-88BC-2732AE5655A2Q26992321-80B26066-03F4-4838-8D6F-4428E7325CB1Q28077637-233D3378-B6CE-4C30-B5CF-FB76FD3EBB8FQ28084315-A40E241E-860C-48AE-80E0-9E873F9FED65Q28730018-F29D36F0-31DD-45B1-BF01-C2792D41E8F2Q33403848-C2FADEBA-216E-42BB-AECE-3D13CE2F1D51Q33672308-F72D794C-7812-45F1-ADD1-1D64A829F3AAQ33876719-C109281E-D911-457C-89C6-6BA501427E04Q33888929-973B34F9-125E-4911-A07E-11F95EBB41FEQ33966102-E5F7D584-B9C0-4572-AB89-1910E9032590Q34023647-CF4EC5AC-4130-478A-98F8-225CFFE972FEQ34130881-D1B0715A-0D40-4327-90FB-45D19B1B9306Q34196301-ECE9EDAD-FECE-49DE-9E0C-FE76ECFAB695Q34338152-A6FE2D5E-0864-4D69-9BAC-A5DD49325281Q34341066-CEF40E88-FA19-421E-B30D-FDF07E4E4C3EQ34431985-2BC50796-8806-465E-96FA-D08FFC186768Q34486386-67EE78F6-2901-4E5A-83BC-02D9FB769F0AQ34575792-6602C789-905C-49F8-B4E9-948A9F6DE523Q34584831-94DF47FA-A5F6-4CE0-9076-EC21A69CB552Q34608705-8F7C5530-B419-4B64-8C7D-5399A0662C33Q34638067-25FFF429-EE98-4B31-AC41-B611D66264FEQ34956588-E6FD306D-7F1E-4075-95C5-2563D322C2C0Q35054821-F9E331C0-313C-45CE-B13A-E98E1161508BQ35073371-AEE0BDE3-2BA2-4322-A866-F371A20A7976Q35170677-C581DAD7-875C-44F4-B76D-506383C91BFDQ35215035-2FF6AE17-CBDF-495B-AE00-17BDE07527ABQ35475576-09EA97A3-5CE0-44D6-9A86-8D5B255C3E95Q35584053-F2AA11DE-C55E-40A1-8DC4-90C38604949BQ35599773-96B7AA92-E32A-4481-93AD-7D1F27158B4BQ35603724-8540168D-D986-4FA4-BD2C-904A29B4FBF1Q35799611-FB57E524-6606-4793-97E8-ECCC3A15B23CQ35879887-FCF3725E-BC9B-493F-AD5E-A4225A590EA5Q35971516-77A719AD-887A-476C-B8B2-480984DEE163Q36055953-80F509F9-7849-479C-B182-6C6EB59A81D4Q36147839-2A0D340F-F2CF-4264-98B1-127FE59BB2C0Q36235699-1E2539E4-2C53-440A-B3D7-203C77450A16Q36253744-B791ED51-E52D-4E66-9BF8-2D2980F7F067
P2860
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@ast
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@en
type
label
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@ast
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@en
prefLabel
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@ast
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@en
P2093
P2860
P356
P1476
Association between the 21-gen ...... from NSABP B-14 and NSABP B-20
@en
P2093
Bernard Fisher
Charles E Geyer
D Lawrence Wickerham
Drew Watson
Eleftherios P Mamounas
Joseph P Costantino
Norman Wolmark
Soonmyung Paik
Steven Shak
P2860
P304
P356
10.1200/JCO.2009.23.7610
P407
P577
2010-01-11T00:00:00Z